New York, May 17, 2026, 05:30 (EDT)
MeiraGTx Holdings plc (MGTX) is under pressure early this week after a late Friday slide knocked back most of its recent gains from pipeline news and funding headlines. The stock closed at $9.40 on Friday, down 5.5% for the day and 4.3% over the last five sessions, market data shows.
MeiraGTx is moving from a research-focused story to one centered around regulatory filings. Last week, the company posted first-quarter results, said it received FDA Breakthrough Therapy Designation for AAV2-hAQP1, which could speed talks with regulators on key drugs for hard-to-treat diseases, and said it’s advancing bota-vec (botaretigene sparoparvovec) toward filings in the U.S., Europe, the U.K., and Japan.
Nasdaq stays closed on Sunday, as usual. The exchange is set to reopen Monday at 9:30 a.m. ET for its regular session and will run until 4 p.m. ET. Next up is Monday, May 18, when investors get the first full look at MeiraGTx’s earnings, any new analyst moves, and how the gene-therapy sector shapes up after the weekend.
MeiraGTx CEO Alexandria Forbes said early 2026 has “materially strengthened MeiraGTx,” giving the company a shot at approval and commercial rollout of two fully owned therapies in the next two years. Forbes also said the company is “working expeditiously” on bota-vec regulatory work. That wording now matters for a small biotech that’s traded more on delivery than on science. MeiraGTx
MeiraGTx kept things tight in Q1, with service revenue dropping to $293,000 from $1.9 million a year earlier. Net loss grew to $46.3 million, or 57 cents per share, compared with $40.0 million last year. Cash and cash equivalents were $71.5 million at March 31, and accumulated deficit reached $862.5 million.
MeiraGTx priced an equity offering in April, selling 11.1 million ordinary shares at $9 apiece for roughly $100 million in gross proceeds. That move adds breathing room for the company but hits current shareholders with dilution. The company says the new capital should fund operations until the second half of 2028 and might pay for launches of bota-vec and AAV-hAQP1 if they clear regulatory hurdles.
Bota-vec is the main swing factor for now. MeiraGTx said in April it would pay $25 million up front to reacquire the program from Johnson & Johnson after working with J&J’s Janssen before. The deal could include more in regulatory, commercial, and royalty milestones. The therapy targets X-linked retinitis pigmentosa, a rare eye disorder that can lead to vision loss.
RBC kept its bullish rating on MeiraGTx, according to MT Newswires by way of MarketScreener, and increased its price target to $25 from $24 on Friday. Shares finished at $9.40. That’s still far below where RBC sees them going.
MeiraGTx isn’t getting lumped in with the rest of pharma right now. Investors are eyeing other names in gene therapy as they try to bring clinical-stage products closer to market. Rocket Pharmaceuticals has posted progress in its cardiovascular gene therapy pipeline, plus got KRESLADI approved. 4D Molecular Therapeutics is taking a late-stage retina gene therapy forward in wet age-related macular degeneration.
MeiraGTx got a big pharma partner last year. Eli Lilly put down $75 million up front and could pay as much as $400 million more in milestones for rights to MeiraGTx’s gene therapy in a rare inherited eye disorder, Reuters reported in November. The deal could be worth over $475 million.
The risk is upfront—regulatory filings miss, trial data can flop, and even after gene therapy approval, rollout is hard, with challenges from manufacturing to reimbursement and patient access. MeiraGTx’s latest 10-Q spells it out: deep losses, no guarantee of profit, need for more funding, and cash could run out quicker than expected.
Investors are set to find out this week if Friday’s drop was just a pause after gains in April, or something more. The company said it won’t have fresh Phase 2 AQUAx2 data for AAV2-hAQP1 until the second quarter of 2027. The next update for bota-vec will be regulatory filings, not new revenue news. All eyes shift to the stock’s Monday open. Moves in small-cap biotech names can run quick when the news flow dries up.
